Article Information
History
- November 26, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Amy J. Schuh1,
- Panayampalli S. Satheshkumar1,
- Stephanie Dietz1,
- Lara Bull-Otterson1,
- Myrna Charles1,
- Chris Edens1,
- Jefferson M. Jones1,
- Kristina L. Bajema1,
- Kristie E.N. Clarke1,
- L. Clifford McDonald1,
- Sadhna Patel1,
- Kendra Cuffe1,
- Natalie J. Thornburg1,
- Jarad Schiffer1,
- Kelly Chun2,
- Monique Bastidas2,
- Manory Fernando2,
- Christos J. Petropoulos2,
- Terri Wrin2,
- Suqin Cai2,
- Dot Adcock2,
- Deborah Sesok-Pizzini2,
- Stanley Letovsky2,
- Alicia M. Fry1,
- Aron J. Hall1 and
- Adi V. Gundlapalli1,4
- 1CDC COVID-19 Response, United States Centers for Disease Control and Prevention, Atlanta, GA
- 2Labcorp, Burlington, NC
- ↵4Correspondence: Adi V. Gundlapalli, MD, PhD, Center for Surveillance, Epidemiology, and Laboratory Services, United States Centers for Disease Control and Prevention, Atlanta, Georgia, 30333; agundlapalli{at}cdc.gov
Posted November 26, 2021.
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic Infection
